Medicines A-Z
Back to Rifafour Tablet

Rifafour Tablet Uses in Pakistan

Rifafour Tablet is a fixed-dose combination anti-tuberculosis medicine used in Pakistan. This guide covers its approved uses, indications, and important information for TB patients and carers.

Compiled by the PakVita Editorial Team · AI-assisted drafting with editorial review · Sourced from DRAP, WHO, BNF · Last updated:

Uses

Quick Answer

Rifafour Tablet (rifampicin, isoniazid, pyrazinamide, ethambutol) is used for the intensive phase treatment of pulmonary tuberculosis. It belongs to the fixed-dose combination anti-TB class and is used under strict medical supervision. Always take it at the correct dose as directed by your doctor or pharmacist.

Primary Uses at a Glance

Intensive phase treatment of pulmonary tuberculosis

Rifafour Tablet is used for the intensive phase treatment of pulmonary tuberculosis. This is the primary approved indication for this fixed-dose combination in Pakistan.

As prescribed by your TB doctor. Weight-based dosing — do not self-adjust.

Drug-sensitive TB (initial intensive phase)

Rifafour Tablet is used for drug-sensitive TB during the initial intensive phase. This is one of the primary approved indications for this four-drug combination in Pakistan.

As prescribed by your TB specialist. Complete the full 2-month intensive phase.

TB treatment under DOTS programme

Rifafour Tablet is used within the DOTS (Directly Observed Treatment Short-course) programme for systematic TB management in Pakistan.

As prescribed and observed under the DOTS programme by a healthcare worker.

Other Uses

  • Adjunct in TB co-infected patients (specialist guidance required)

Rifafour Tablet Uses (Fayde / Kis kaam aati hai)

Rifafour Tablet contains rifampicin, isoniazid, pyrazinamide, and ethambutol HCl and belongs to the fixed-dose combination anti-tuberculosis group. Below are all the approved and common uses of Rifafour Tablet in Pakistan.

Primary Uses (Mukhya Istemal)

  • Intensive phase treatment of pulmonary tuberculosis
  • Drug-sensitive TB (initial intensive phase)
  • TB treatment under DOTS programme

Who Should Take It (Kin logon ke liye)

  • Newly diagnosed TB patients in the intensive treatment phase
  • Adults and adolescents with pulmonary TB as confirmed by a doctor
  • Patients enrolled in a DOTS (Directly Observed Treatment Short-course) programme

When NOT to Use Rifafour Tablet (Kab nahi leni chahiye)

  • If you are allergic to rifampicin, isoniazid, pyrazinamide, or ethambutol
  • If you have active liver disease or severe hepatic impairment
  • If you have pre-existing optic neuritis or severe visual impairment

Summary

Rifafour Tablet is prescribed for intensive phase treatment of pulmonary tuberculosis. Complete the full TB course — stopping early causes drug resistance. Always consult a doctor before starting or stopping this medicine.

The information in this guide is for educational purposes only.

Frequently Asked Questions

For which conditions is Rifafour Tablet most effective?

Rifafour Tablet is most effective for intensive phase treatment of pulmonary tuberculosis in adults and adolescents. Always take it for the condition your doctor has prescribed it for and complete the full TB course.

Can Rifafour Tablet be taken without a doctor's prescription?

Rifafour Tablet is a prescription (Rx) medicine. Do not take it without a doctor's advice. TB treatment requires specialist supervision.

How long does Rifafour Tablet take to show results?

TB treatment is measured in months, not days. The intensive phase typically lasts 2 months, followed by a continuation phase. Follow your doctor's treatment schedule and never stop early.

Can Rifafour Tablet be taken long-term?

Rifafour Tablet is used for the intensive phase (typically 2 months). Long-term TB treatment is managed by your doctor with regular monitoring. Your doctor will decide when to transition to the continuation phase.

What should I do if Rifafour Tablet does not seem to work?

If symptoms persist or worsen, consult your TB doctor immediately. Do not increase the dose on your own. Drug resistance testing may be needed.

Sources

  1. DRAP Registered Products Database — Drug Regulatory Authority of Pakistan
  2. WHO Model List of Essential Medicines, 23rd ed. (2023) — World Health Organization
  3. British National Formulary (BNF) — BMJ Group & Pharmaceutical Press

Medical disclaimer

This page is for educational use only and does not replace professional medical advice. Always confirm diagnosis, dose, and interactions with a qualified doctor or pharmacist before starting or changing any medicine.